Meeting
2021 ASCO Annual Meeting
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Authors
Katherine Tarlock
Seattle Children's Hospital, Seattle, WA
Katherine Tarlock , Xiaowei Liu , Charles G. Minard , Sarah Menig , Joel M. Reid , Emasenyie Isikwei , Sharon Bergeron , Terzah M Horton , Elizabeth Fox , Brenda Weigel , Todd Michael Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT03813147
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10018)
DOI
10.1200/JCO.2021.39.15_suppl.10018
Abstract #
10018
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
First Author: Uday R. Popat
Poster
2018 ASCO Annual Meeting
Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.
First Author: Dietger Niederwieser
Poster
2014 ASCO Annual Meeting
ASCO 2014: High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse.
First Author: Simon Abi Aad
Poster
2013 ASCO Annual Meeting
Phase I study of midostaurin and azacitidine in relapsed and elderly AML.
First Author: Brenda W. Cooper